Literature DB >> 8283928

Lipoprotein disorders in diabetes mellitus.

W V Brown1.   

Abstract

In IDDM or NIDDM, the total plasma cholesterol and triglycerides are usually within normal limits when the blood glucose is controlled. Marked hypertriglyceridemia can develop with loss of glycemic control and is often due to superimposed genetic abnormalities in lipoprotein metabolism. Tight control in IDDM usually reduces LDL and VLDL to normal levels and may raise HDL above the normal range. Low HDL cholesterol and mild to moderate elevations of VLDL triglyceride are common in NIDDM if obesity or proteinuria is also present. Both HDL and LDL may be smaller and more dense and may be enriched with triglyceride as compared with cholesterol. These abnormalities may require weight loss for control. The increased incidence of cardiovascular disease in diabetes is unexplained but is amplified by the well-defined cardiovascular risk factors. The new American Diabetes Association guidelines call for treatment of high triglycerides and LDL cholesterol to be aggressively reduced. Triglycerides should be under 200 mg/dL, are considered borderline high between 200 and 400 mg/dL, and high when above 400 mg/dL. Low HDL is defined as less than 35 mg/dL. Control of obesity with diet and exercise and reduced intake of saturated fat and cholesterol are important first steps. If needed, drug therapy is appropriate to reduce LDL to levels below 130 mg/dL in all adult diabetics and below 100 mg/dL in those with cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8283928     DOI: 10.1016/s0025-7125(16)30180-8

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  11 in total

Review 1.  Dyslipidemia in systemic lupus erythematosus.

Authors:  Melinda Zsuzsanna Szabó; Peter Szodoray; Emese Kiss
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

2.  Succinic acid monoethyl ester, a novel insulinotropic agent: effect on lipid composition and lipid peroxidation in streptozotocin-nicotin-amide induced type 2 diabetic rats.

Authors:  Ramalingam Saravanan; Leelavinothan Pari
Journal:  Mol Cell Biochem       Date:  2006-09-28       Impact factor: 3.396

3.  Lipoprotein profile in limited systemic sclerosis.

Authors:  Eduardo F Borba; Claudia T L Borges; Eloísa Bonfá
Journal:  Rheumatol Int       Date:  2005-02-08       Impact factor: 2.631

4.  Role of Omega-3 Fatty Acids on Lipid Profile in Diabetic Dyslipidaemia: Single Blind, Randomised Clinical Trial.

Authors:  Shaylika Chauhan; Hanish Kodali; Jawad Noor; Karuna Ramteke; Vidisha Gawai
Journal:  J Clin Diagn Res       Date:  2017-03-01

5.  Lipoprotein (a) in type 2 diabetes mellitus: Relation to LDL:HDL ratio and glycemic control.

Authors:  Seema Singla; Kiranjeet Kaur; Gurdeep Kaur; Habir Kaur; Jasbinder Kaur; Shivani Jaswal
Journal:  Int J Diabetes Dev Ctries       Date:  2009-04

6.  High frequency of lipoprotein risk levels for cardiovascular disease in Takayasu arteritis.

Authors:  Jozélio Freire de Carvalho; Eloísa Bonfá; Mailze C Bezerra; Rosa Maria Rodrigues Pereira
Journal:  Clin Rheumatol       Date:  2009-03-13       Impact factor: 2.980

7.  Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency.

Authors:  R Bucala; Z Makita; G Vega; S Grundy; T Koschinsky; A Cerami; H Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

8.  Serum Lp(a) in diabetics with and without evidence of clinical nephropathy-A preliminary study.

Authors:  S Jaya Kumari; Nivedita Jayaram; Lloyd Vincent; T Venkatesh
Journal:  Indian J Clin Biochem       Date:  2002-01

9.  Antidiabetic and antioxidant activities of ethanolic extract of Semecarpus anacardium (Linn.) bark.

Authors:  Md Ashraf Ali; Mir Imam Ibne Wahed; Naznin Ara Khatune; Bytul Mokaddesur Rahman; Ranjan Kumar Barman; Md Rafiqul Islam
Journal:  BMC Complement Altern Med       Date:  2015-04-29       Impact factor: 3.659

10.  Lack of antilipoprotein lipase antibodies in Takayasu's arteritis.

Authors:  Jozélio Freire de Carvalho; Rosa Maria Rodrigues Pereira; Vilma Santos Trindade Viana; Eloísa Bonfá; Yehuda Shoenfeld
Journal:  Clin Dev Immunol       Date:  2009-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.